论文部分内容阅读
目的探讨硼替佐米应用于初治多发性骨髓瘤患者的诱导化疗及自体外周血造血干细胞移植预处理方案的可行性和效果。方法对3例初治多发性骨髓瘤患者给予PAD(硼替佐米+表柔比星+地塞米松)方案化疗4疗程,后进行PMD(硼替佐米+马法兰+地塞米松)方案预处理的自体外周血造血干细胞移植。动员方案为环磷酰胺+硼替佐米+地塞米松联合G-CSF 5~10μg/(kg.d)。结果3例患者在4疗程PAD方案化疗后达VGPR,干细胞采集顺利,移植后造血功能顺利重建,移植后中性粒细胞和血小板临床植入的时间分别为14、16、16d和25、29、22d。结论万珂应用于初治多发性骨髓瘤患者的诱导治疗及自体外周血造血干细胞移植的预处理,安全有效,值得临床进一步研究探索。
Objective To investigate the feasibility and effect of bortezomib in the induction of chemotherapy and the pretreatment of autologous peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Methods Three patients with newly diagnosed multiple myeloma were treated with PAD (bortezomib + epirubicin +) for 4 courses of chemotherapy and then pretreated with PMD (bortezomib + melphalan + dexamethasone) Autologous peripheral blood stem cell transplantation. Mobilization program for cyclophosphamide + bortezomib + dexamethasone combined G-CSF 5 ~ 10μg / (kg.d). Results Three patients achieved VGPR after 4 cycles of PAD regimen, stem cell collection was successful, and hematopoietic function was successfully reconstructed after transplantation. The time of clinical implantation of neutrophils and platelets after transplantation was 14, 16, 16 and 25, 22d. Conclusion Velcro used in patients with newly diagnosed multiple myeloma induction therapy and autologous peripheral blood stem cell transplantation pretreatment, safe and effective, worth further clinical exploration.